Intramedullary osteosarcoma Treatment Market

Intramedullary osteosarcoma Treatment Market:Global Industry Analysis 2015 - 2019 and Opportunity Assessment; 2020 - 2030

Market Overview

Intramedullary osteosarcoma is the most common sarcoma of the bone. It is also referred to as conventional osteosarcoma. It represents about 80% of the Osteosarcoma cases mostly affecting youth between 20-25 years.

Intra medullary osteosarcoma is a high-grade malignant sarcoma which arises from the center of the bone. Its prevalence is slightly higher in the male population, mostly occurring during adolescent age.

Intramedullary osteosarcoma can be further divided into osteoblastic, chondriblastic and fibroblastic osteosarcomas. Increasing levels of Serum alkaline phosphatase can be a   marker for this disease. Early stage diagnosis involves X-ray and MRIs.

Computer tomography scans can help in identifying cortical irregularities, fracture sites, mineralization, and neurovascular involvement. Other scans like scintigraphy and PET scans can help identify metastasis.

Further Confirmatory test like a biopsy is essential in diagnosis. The most common chemotherapy agents used for treatment are methotrexate with leucovorin, doxorubicin, cisplatin, and ifosfamide.

Etoposide can be used to treat metastatic conditions. Use of chemotherapy for intramedullary osteosarcoma has shown to increase the survival rate by five years. Post resection chemotherapy is recommended as soon as possible.

Sirolimus, Everolimus are mTOR inhibitors used in treatment. Disruption of angiogenesis is another way of targeting therapy. A VEGFR, PDGFR inhibitor called Pazopanib has shown some efficacy in metastatic Osteosarcoma.

Intramedullary osteosarcoma Treatment Market: Drivers and Restraints-

Intramedullary osteosarcoma is a threat to the young population worldwide, and its increasing incidences can be a driving force for the market. Research and development for discovering new treatment options for conventional osteosarcoma can act as a market driver.

Rising demand for better and novel treatment options can upswing the intramedullary osteosarcoma growth. Increasing prevalence of intramedullary osteosarcoma in young population is a major driving force for the intramedullary osteosarcoma market.

Government funds for expanding research for osteosarcoma treatment can support the growth of the market. However the cost of the treatments like chemotherapy, radiation etc. can hinder the market growth.

Treatments like chemotherapy have substantial side effects on human health. This can be a cause of restraint for the market growth. A collaboration of hospitals and research labs can benefit the scope of treatment with new findings like novel immunotherapy drugs.

Hospitals for In COVID-19 pandemic scenario, the valuable medical resources and treatment options being unavailable can patient’s treatment can halt or get neglected.

According to WHO, the osteosarcoma incidence rates are consistent throughout the world, while they are slightly higher in Latin America, Sudan and Uganda reporting slightly higher rates than in other regions. Increasing focus on optioning premium cancer care in developing regions can contribute majorly for the intramedullary osteosarcoma market.

Intramedullary osteosarcoma Treatment Market: Overview

Amongst all the bone cancer types, intramedullary osteosarcoma is the most common cancer and can be expected to have a large huge market size in the next decade. Various research institutions and hospital universities are undergoing research for osteosarcoma treatment.

Current treatment options available in the market are surgery, chemotherapy and radiation therapy. Collaborations of research academia and hospitals for discovering novel targets are seen to take place in the US for intramedullary osteosarcoma treatment.

Recent attractive osteosarcoma target is the mTOR pathway that stimulates proliferation, angiogenesis and survival and extensive research is going on in this are especially in US and UK.

Intramedullary osteosarcoma Treatment Market: Region-wise Outlook

North America region dominates the current intramedullary osteosarcoma market as many clinical trials are undergoing in the USA for intramedullary osteosarcoma.

Increasing healthcare expenditure by government in developed countries make the intramedullary osteosarcoma treatment market adoptive in these regions. Increasing prevalence rate of intramedullary osteosarcoma can be a opportunistic factor for the intramedullary osteosarcoma market growth.

Intramedullary osteosarcoma Treatment Market: Key Market Participants

Some of the market participants of intramedullary osteosarcoma treatment market are

  • Novartis International AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.

The research report on intramedullary osteosarcoma treatment presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies. The research report on intramedullary osteosarcoma treatment market provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain)
  • Eastern Europe (Poland, Russia)
  • Asia Pacific (India, ASEAN, Australia & New Zealand)
  • China
  • Japan
  • Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.

The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current, and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint

Intramedullary osteosarcoma Treatment Market: Segmentation

By treatment type :

  • Chemotherapy
  • Combination therapy
  • Targeted therapy
  • Others

By distribution channels:

  • Hospital pharmacies
  • University hospitals pharmacies

Need specific information?

In the news

How Businesses Can Utilize Market Research to Create Reactive, Recession-proof Strategies for Survival

by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights

Our Clients

View Our Reports from Healthcare

View Reports


Intramedullary osteosarcoma Treatment Market